Background: Ischemic injury and the rejection process are the main reasons for graft failure in tracheal transplantation models. To enhance the acceptance, we investigated the influence of mesenchymal stem cells (MSCs) on tracheal allografts. Methods: Extracted tracheal grafts from New Zealand white rabbits were cryopreserved for 4 weeks and orthotopically transplanted (control group A, n=8). In group B (n=8), cyclosporin A (CsA, 10 mg/kg) was injected daily into the peritoneal cavity. In group C (n=8), MSCs (1.0×10 7 cells/kg) from the same donor of the tracheal allograft, which had been pre-cultured for 4 weeks, were infused intravenously after transplantation. In group D (n=8), MSCs were infused and CsA was injected daily. Four weeks after transplantation, gross and histomorphological assessments were conducted for graft necrosis, measuring the cross-sectional area of the allograft, determining the degree of epithelization, lymphocytic infiltration, and vascular regeneration. Results: The morphologic integrity of the trachea was retained completely in all cases. The cross-sectional areas were decreased significantly in group A (p=0.018) and B (p=0.045). The degree of epithelization was enhanced (p=0.012) and the lymphocytic infiltration was decreased (p=0.048) significantly in group D compared to group A. The degree of vascular regeneration did not differ significantly in any of the groups. There were no significant correlations among epithelization, lymphocytic infiltration, and vascular regeneration. Conclusion: The administration of MSCs with concurrent injections of CsA enhanced and promoted epithelization and prevented lymphocytic infiltration in tracheal allografts, allowing for better acceptance of the allograft.
INTRODUCTION
Treatments for long segmental and circumferential tracheal defects remain a challenge. Although synthetic and bio-synthetic flaps [1] and reconstitution of the trachea through tissue engineering [2, 3] have been investigated, their clinical applicability is questionable because of functionality, biomechanics, and viability. In tracheal transplantation models, the restoration of epithelization and vascularization, as well as immunosuppression, are necessary to enhance the acceptance of an allograft.
Tracheal revascularization and epithelial regeneration are concomitant processes and an adequate blood supply to the tracheal allograft plays a great role in preventing mucosal
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− 329 − disintegration [4] . The tracheal blood supply has been restored by revascularization from tracheal vessels [5] and a pedicled flap of omentum or muscles [6, 7] . Since the airway complications after lung transplantation are not affected by the presence or absence of a flap wrapped around the bronchial anastomosis [8, 9] , and the immunologic process is not related to the degree of revascularization, the histological alterations seen in tracheal allograft are therefore produced by activation of the immune response rather than transient ischemia by itself [10] .
The trachea is subject to the same immunological principles of transplantation as all other transplanted tissues [11, 12] . The human tracheal mucosa expresses HLA class II molecules, and this may be the major antigenic structure that is responsible for the immunologic response against allogenic tracheal transplants [13, 14] . To prevent the mucosal rejection mediated by the mononuclear cells [4] , continuous immunosuppression with cyclosporin A (CsA) is necessary to maintain an optimal condition for tracheal allograft survival [15] . However, CsA does not alter the injuries sustained by the allograft through the phases of early ischemia [16] , and the resulting immunosuppression may increase the risk of infection or aggravate a malignant process; therefore, attenuation of tracheal allograft antigenicity is required, which can be greatly reduced by removing the tracheal epithelium and by cryopreservation [17] . However, if the inner surface of the trachea is not remodeled by the recipient's epithelium, fibro-proliferative tissue can enter the tracheal lumen and will lead to tracheal obstruction [18] , emphasizing the role of the epithelium in controlling airway obliteration [19] and affecting the graft's antigenicity [20] .
Another method to reduce the antigenicity is the induction of chimerism by injection of mesenchymal stem cells (MSCs). Mixed allogenic chimerism induces donor-specific tolerance and prevents the development of fibro-proliferative obstruction [21] of the tracheal allograft by improving epithelial regeneration [22] and neovascularization [23] , as well as modulating the recipient's immune response [24] .
To develop a transplantation method to enhance the acceptance of an allograft, we conducted a study to determine the influence of MSCs on the survival of cryopreserved tracheal allograft in rabbits.
METHODS

1) Animal
Male New Zealand White rabbits weighing 3.0 to 3.5 kg were purchased from Samtacho Inc. (Osan, Korea) and cared for in accordance with the international guideline for laboratory animal care.
2) Harvesting and culture of mesenchymal stem cells of donor rabbits
The donor rabbits were sedated with Zoletil 50 (Tilentamin ＋Zolazepam; Virbac Laboratories, Carros, France) and then sacrificed with an intravenous injection of KCl. Under sterile conditions, both femurs were dissected and disarticulated.
Both ends of each femur were excised and the marrows were flushed out with 5 mL of low-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco/BRL, Grand Island, NY, USA) and 1 mL (5,000 IU) heparin. The heparinized bone marrow in the DMEM medium was transferred into a 50 mL Falcon tube and centrifuged at 600 g for 10 minutes, and the supernatant was discarded. The resulting cell pellet was resuspended with 7 mL low-glucose DMEM medium and 4% acetic acid. The nucleated cells were adjusted to a density of
1×10
5 cell/mL and were cultured in low-glucose DMEM medium with 10% fetal bovine serum (FBS; Gibco/BRL) and 1% antibiotic solution (penicillin-streptomycin; Gibco/BRL) at 
3) Harvesting and cryopreservation of trachea allograft
After harvesting the bone marrow, the whole trachea was harvested through a median cervical incision. The harvested trachea was then trimmed off to a 2 to 3 cm segment. The diameter of the graft was measured and then stored in a cryogenic vial filled with the freezing solution containing low-glucose DMEM, 10% dimethyl sulfoxide (DMSO; Sigma), 40% FBS, and 1% antibiotic solution. The tracheal graft was 
4) Tracheal transplantation
A weight-matched male New Zealand White rabbit was in- 
5) Experimental design
The cryopreserved tracheal grafts were transplanted orthotopically, and the transplant recipient rabbits were divided into four groups. In group A (n=8), no additional interventions were performed. In group B (n=8), 10 mg/kg Sandimmun CsA was injected daily.
6) Assessment of the tracheal allograft
Four weeks after transplantation, the recipients were sacrificed with intravenous injection of KCl, and the tracheal allografts were extracted en bloc including the native trachea. 
RESULTS
1) Macroscopic assessments of tracheal allograft
Four weeks after transplantation, the morphologic integrity of the extracted tracheal allograft had been completely retained in all cases without dehiscence or necrosis. The vessels from adjacent wrapped tissues had regenerated well in all of the cases. The morphologic figures of the tracheas had been preserved well in groups C and D, but were shrunken and had become O-shaped in groups A and B.
The sizes of the tracheal allografts estimated before transplantation were about 5×7 mm in rabbits weighing 3.0 to 3.5 kg and there were no differences between the proximal and distal ends, or between each of the groups. The cross-sectional areas tended to have decreased in all of the groups after transplantation, but they had decreased significantly in groups A (p=0.018) and B (p=0.045) ( Table 1) .
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− 332 − In group A and B, the lumina of the tracheal allografts were significantly decreased in size and their walls were shrunken, but in group C and D, the lumina and the walls were preserved well. There were no significant differences in the cross-sectional area among group C and D before and after TPX. NS, not significant. The trachea was long believed to have weak antigenicity, but it is subject to the same immunological laws of transplantation as all other transplanted tissues [11, 12] . Human tracheal mucosa, which expresses HLA class II molecules, may be the major antigenic structure responsible for triggering immunologic action in allogenic tracheal transplantation [13, 14] .
This major histocompatibility complex (MHC)-oriented alloreactivity plays an important role in acute rejection. Epithelial cells can function as antigen-presenting cells when they express MHC class I and II antigen on their surface [25] .
Lymphocytic infiltration is the precursor of fibrous airway obliteration, which is aggravated by the initial ischemic phase, and followed by complete epithelial loss and fibrous obliteration [26] . Therefore, immunosuppression is necessary to preserve the optimal morphologic and functional conditions in order to, in turn, improve the viability of tracheal allograft epithelium [27] .
CsA, a widely accepted immunosuppressant, inhibits activation and proliferation of T-lymphocytes. It can preserve the viability of a transplanted trachea [4, 10, 28] , markedly reduces the development of fibroproliferation in the allograft [29] , and inhibits the infiltration of monocytes/macrophages in the acute phase [30] . An adequate dose of CsA for intravenous injection in rabbits is 10 mg/kg [4, 15] , and continuous immunosuppression is necessary to maintain optimal conditions for tracheal allograft survival [15] . On the other hand, King et al. [29] reported that CsA does not reduce inflammation or airway epithelial cell injury, and Neuringer et al. [16] reported that although CsA can delay airway fibrosis, it does not alter the progression of the allograft through the phases of early ischemic injury. In this study, we found that the tracheal lumen shrunk significantly in the CsA group.
Epithelization, lymphocytic infiltration, and vascular regeneration did not improve compared to the control group.
We suggest that CsA may or may not reduce the severity of acute rejection, but it does not prevent the fibrous proliferation and luminal obliteration that can be protected by epithelial regeneration. If epithelization is interrupted by other causes, such as ischemia or infection, fibrous proliferation will eventually develop. Moreover, CsA may increase the risk of infection, aggravate the malignant process, or cause renal toxicity. Therefore, attenuation of tracheal allograft antigenicity is required in addition to immunosuppression.
The antigenicity of a tracheal allograft can be greatly reduced by removing the epithelium [17] , and various methods has been investigated, such as cryopreservation [31, 32] , irradiation [33] , photodynamic therapy [34] , and detergent treatment [35] . Cryopreservation has been the most favorable technique to maintain long-term tissue viability and structural integrity. It can also reduce the immune response and the acute rejection process by depletion of the antigenic donor epithelia [17, 20, 32, [36] [37] [38] [39] . It has been postulated that the freezing and thawing processes involved in cryopreservation [36, 40] as well as long-term cryopreservation of more than one month [40] Even though acute rejection was reduced by cryopreservation, mild but chronic rejection responses continued, resulting in occlusion of the transverse intercartilaginous arteries and consequent progressive atrophy [38] . To reduce allograft antigenicity further, the inner surface of the trachea should be remodeled and replaced by the recipient's epithelium [20] .
This can prevent chronic rejection even after withdrawal of immunosuppression [41] . If the denuded lining of the tracheal allograft is not promptly covered by the recipient's epithelium,
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− 337 − fibroproliferative tissues will enter the tracheal lumen via the membranous part [18] and cause airway obliteration and also cause the rejection process to continue unchecked. These processes are more pronounced in a heterotopic transplant model than in an orthotopic model because the growth of the recipient's epithelium over the denuded donor trachea does not occur [18, 19] . Epithelial re-growth from the host limits the progression of obliterative airway disease [19] , which can be explained by an experiment showing that co-culturing with epithelial cells leads to deregulation of contact inhibition of the normal fibroblasts [2] .
Another method for increasing the acceptance of an allograft is the formation of chimerism that can lead to an acquired donor-specific tolerance [42] . Mixed allogenic chimerism through infusion of MSCs induces donor-specific tolerance and prevents development of the fibroproliferative obstruction of a tracheal allograft in a heterotopic transplant model [21] . Simultaneous administration of donor MSCs following reduced intensity conditioning prevented tracheal graft rejection by preserving the lining epithelial cells and reducing lymphocytic infiltration. It was found that allograft acceptance is dependent on the co-administration of donor MSCs rather than the preconditioning of bone marrow [22, 24] . MSCs can also increase the neovascular response in a limb ischemia model [23] and myocardial infarction model [43] . Therefore, This study has brought several issues to light concerning the methods associated with using MSCs to enhance allograft survival. Further research with a larger sample size and longer follow-up will clarify these issues. First, it is important to understand whether intravenous administration of MSCs is superior to local implantation. Although intravenously administered MSCs are capable of homing into the sites of tissue damage or inflammation [43, 44] , further study will be needed to compare this capability in a tracheal transplantation model with that in other models.
Second, the effective dose of MSCs has to be determined.
Le Blanc et al. [45] reported that a high concentration of
MSCs induced the inhibition of lymphocyte proliferation, whereas less suppression or a marked lymphocyte proliferation occurred with a low concentration of MSCs. In contrast, Bartholomew et al. [46] reported that the administration of an increased number of MSCs did not extend skin graft survival.
In our study, two rabbits that received less than 0.5×10 7 MSCs/kg died of tracheal stenosis that showed severe lymphocytic infiltration. These two rabbits were not included in this study because of the low MSC density. However, in the 16 rabbits that received the dose of 1. 
